SLC5A2 and kidney disorder: Therefore, almost all scientific guidelines now recommend specific treatments for patients with type 2 diabetes based on CVOTs data, namely adding to metformin a SGLT-2 inhibitor or a GLP-1RA with proven CV disease benefit in patients with type 2 diabetes and CV disease, established kidney disease, or HF [7–10].